Keyphrases
Receptor Tyrosine Kinase
100%
Lapatinib
100%
Therapeutic Agents
100%
Mammary Cancer
100%
Multiple Signaling Pathways
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
50%
Epidermal Growth Factor Receptor
50%
Tumor
25%
N-ethyl-N-nitrosourea
25%
Receptor Tyrosine Kinase Inhibitor
25%
Intravenous Injection
12%
Insulin-like Growth Factor 1 Receptor (IGF1R)
12%
Small Molecules
12%
Mammary Tumor
12%
Protein Targeting
12%
Cancer Development
12%
Apoptosis
12%
Protein Phosphorylation
12%
Cyclin D1 (CCND1)
12%
Signaling Molecules
12%
Highly Effective
12%
Downstream Targets
12%
Estrogen Receptor-positive
12%
Sprague-Dawley Rats
12%
Immunoreactivity
12%
Cell Cycle Arrest
12%
Therapeutic Outcome
12%
Glycogen Synthase Kinase 3 (GSK3)
12%
Proliferation Apoptosis
12%
Preventive Efficacy
12%
Tumor-bearing Animals
12%
Phosphorylated Epidermal Growth Factor Receptor
12%
Animal Treatment
12%
Protein Array Analysis
12%
Pharmacology, Toxicology and Pharmaceutical Science
Lapatinib
100%
Breast Cancer
100%
Protein Tyrosine Kinase
100%
Gamma Urogastrone
50%
Epidermal Growth Factor Receptor 2
50%
Epidermal Growth Factor Receptor
37%
N-Nitroso-N-Methylurea
25%
Protein Tyrosine Kinase Inhibitor
25%
Estrogen Receptor
12%
Sprague Dawley Rat
12%
Malignant Neoplasm
12%
Biological Marker
12%
Cyclin D1
12%
Protein P53
12%
Neoplasm
12%